XNAS · Healthcare · Biotechnology
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | Q1 2026 | -0.27 | -1.25 | -362.96% | $0 | ❌ Miss | -3.71% | -13.55% | — |
| 2026-03-19 | Q4 2025 | -0.50 | -0.50 | +0.00% | $1.1M | ➖ Inline | +2.00% | -23.37% | -20.33% |
| 2025-11-06 |
| Q3 2025 |
| -0.61 |
| -0.49 |
| +19.67% |
| $3.2M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-05 | Q2 2025 | -1.71 | -0.68 | +60.23% | $2.7M | ✅ Beat | +18.75% | -1.20% | +2.40% |
| 2025-03-31 | Q4 2024 | -1.36 | -1.25 | +8.09% | $3.3M | ✅ Beat | -30.48% | -44.76% | +0.48% |
| 2024-11-14 | Q3 2024 | -1.91 | -1.70 | +10.99% | $2.9M | ✅ Beat | -0.75% | +3.02% | -12.56% |
| 2024-08-01 | Q2 2024 | -1.67 | -2.03 | -21.56% | $2.5M | ❌ Miss | +1.21% | -9.01% | +6.48% |
| 2024-05-07 | Q1 2024 | -2.12 | -2.05 | +3.30% | $2.1M | ✅ Beat | +0.93% | -3.15% | -40.31% |
Showing last 8 quarters.